Updated:
Longliv Ventures
Longliv Ventures is the venture arm of a European pharmaceutical family, investing in digital health and AI startups from Paris and Israel.
Longliv Ventures
Founded by the family behind one of Europe's largest generic drug manufacturers, Longliv Ventures translates deep pharmaceutical operating experience into early-stage technology investing. The firm's founding wealth traces to the consolidation of European generics manufacturing, providing a capital base tied to healthcare supply chains rather than financial services. With offices in Paris, Ramat Hasharon, Ra'anana, New Brunswick, and Mountain View, the firm mirrors the geographic footprint of the family's operating businesses, maintaining a strong Israel-based deal-sourcing presence alongside a US outpost in New Jersey's pharma corridor. Longliv Ventures concentrates on digital health, enterprise AI, and software platforms that interface with regulated healthcare ecosystems. The firm invests primarily at Seed to Series A stages, favoring startups where clinical validation or regulatory pathway insight can create asymmetric information advantages. Confirmed portfolio holdings remain closely held and are not publicly enumerated. The investment team draws on the family's pharmaceutical manufacturing expertise to evaluate health-tech deals, assessing technical feasibility and FDA or EMA regulatory trajectories before commitment. The firm maintains a lean investment team split across European and Israeli offices, with its Mountain View location providing proximity to US-based health-tech founders and Silicon Valley co-investors. No AUM or deployment figures are publicly disclosed. The principal family's operating businesses — spanning pharmaceutical manufacturing and distribution across Europe — provide a strategic lens for Longliv's direct investment activity, creating the possibility of commercial partnerships between portfolio companies and the manufacturing base. Adjacent vehicles, including philanthropic foundations, are not publicly detailed. Longliv Ventures' structural distinction lies in its tight coupling to an operating pharmaceutical business. Unlike generalist family offices that invest at arm's length from their wealth-origin industry, Longliv deploys capital in sectors where the family's operating companies can serve as launching customers, distribution partners, or clinical trial sites for portfolio companies — a model that resembles strategic corporate venture capital more than passive family office allocation.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
France
City
Paris
Corporate office
Paris, France
Additional offices
New Brunswick, United States · Mountain View, United States · Ramat Hasharon, Israel · Ra'anana, Israel
Sector focus
Frequently asked questions
Who runs investment decisions at Longliv Ventures?
Longliv Ventures does not publicly name its investment committee or managing directors. Investment decisions are understood to be closely held by the founding pharmaceutical family and a small internal team, with operating principals drawing on the family's generics manufacturing expertise for deal evaluation.
Where does the underlying wealth come from?
The family wealth behind Longliv Ventures originated in generic pharmaceutical manufacturing, consolidated across European markets. This operating history gives the firm a specialized lens for evaluating health-tech investments where manufacturing scale and regulatory knowledge are differentiating factors.
Is Longliv Ventures structured as a family office or does it operate like a venture firm?
Longliv Ventures functions as the direct investment arm of a single-family office with an operational venture mandate. It deploys capital in Seed to Series A rounds, primarily in digital health and enterprise AI, but does not raise external funds or operate as a fund manager open to outside limited partners.
What investment stages does Longliv Ventures typically target?
The firm targets early-stage companies from Seed through Series A, where the family's pharmaceutical operating experience can provide the greatest leverage in assessing technical risk and regulatory pathways. Later-stage investments are not a stated focus.
Does Longliv Ventures participate in fund commitments or only direct deals?
Publicly available information indicates a preference for direct investments in operating companies. No fund-of-funds activity or LP commitments to external venture funds are disclosed, suggesting the firm concentrates its capital and sourcing effort on direct equity positions.
How is Longliv Ventures related to the family's pharmaceutical operating businesses?
Longliv Ventures is the venture investment vehicle of the same family that controls a major European generic pharmaceutical manufacturer. The relationship potentially enables portfolio companies to access manufacturing expertise, distribution channels, and clinical infrastructure, though formal commercial arrangements are not publicly detailed.
Which sectors does Longliv Ventures explicitly avoid?
No publicly stated sector exclusions exist. The firm's investment activity concentrates on digital health and enterprise AI that intersects with regulated healthcare, suggesting a de facto avoidance of sectors outside its pharmaceutical domain expertise, such as consumer tech, hard infrastructure, or financial services.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: